Serina Therapeutics (SER) 10-Q2024 Q3 Quarterly report

Filed: 12 Nov 24, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: assist, disposal, Explanatory, fluctuate, headcount, imputed, insignificant, lab, margin, nonpayment, restraint, Serena, software, subcontractor, systematic, team

Removed: addressed, affiliate, aforementioned, Alameda, allocable, allocate, amortized, appointment, approach, approximately, Article, assert, authorization, awarded, body, bonded, breach, capable, capitalize, carry, cease, circumstance, commenced, competent, comply, consecutive, conservator, consignment, contested, continuously, correct, court, created, criteria, cumulative, custodian, damage, declare, defer, define, destruction, detailed, determination, discharged, dismissal, dismissed, Document, emerging, enforceability, exemption, experimentation, fail, fall, guaranteed, important, incomplete, incorrect, inherently, injunction, innovative, insolvency, instituted, invalid, joint, judicial, Jumpstart, jurisdiction, lien, listing, longer, member, month, negotiated, NIH, official, perfected, personal, petition, practical, proceeding, prohibit, prohibited, real, receiver, receivership, reduced, relief, remedied, remedy, repeated, representation, requirement, requiring, restrictive, retrospective, revoked, satisfied, selling, sequestrator, shareholder, Simplifying, sixty, source, standalone, subjective, sum, superior, suspended, Targeted, theft, thereunder, therewith, trustee, understanding, undismissed, unenforceable, unlawful, unremedied, unstayed, vacated, valid, warranty, withdrawn, withheld, work, writ, writing, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SER similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Serina Therapeutics, Inc. (the “Company”) for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Steve Ledger, Chief Executive Officer, and Gregory S. Curhan, Chief Financial Officer, of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 12, 2024

/s/ Steve Ledger
Steve Ledger
Chief Executive Officer

/s/ Gregory S. Curhan
Gregory S. Curhan
Chief Financial Officer